BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Aderis Pharmaceuticals To Participate In The 1st Annual Biotechnology Industry Organization (BIO) Emerging Company Investor Forum


10/19/2005 5:11:46 PM

HOPKINTON, Mass., Oct. 7 /PRNewswire/ -- Aderis Pharmaceuticals announced today that the CFO and Chief Commercial Officer, Kenneth Rice Jr., will present a corporate and clinical program update on Thursday, October 14 at 11:10 a.m. (PDT) at the BIO Emerging Company Investor Forum. The forum will take place October 13-15 at the Palace Hotel in San Francisco.

BIO's Emerging Company Investor Forum, hosted by Lazard and Banc of America Securities, and co-hosted by CIBC World Markets, Pacific Growth Equities, and Citigroup, addresses an unmet need identified by the investment community and industry executives for a conference exclusively focused on emerging public and late-stage private companies in the biotechnology industry.

About Aderis Pharmaceuticals

Aderis Pharmaceuticals is a private, biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and inflammatory disorders. The Company currently has five product candidates in nine internal or partnered clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG for the development and commercialization of Neupro(TM) (rotigotine transdermal system), a proprietary dopamine agonist formulated as a once daily, continuous delivery, transdermal patch to treat Parkinson's disease. NDA and MAA applications for the Neupro(TM) patch have been recently filed. Rotigotine has also completed Phase IIb trials for the treatment of Restless Legs Syndrome and a nasal spray formulation is in Phase I testing as a rescue medication for Parkinson's disease. The Company also has development and commercialization collaborations with King Pharmaceuticals. Aderis Pharmaceuticals' product pipeline includes small molecule, receptor agonists and antagonists for the treatment of Parkinson's disease, Restless Legs Syndrome, atrial fibrillation, diabetic foot ulcers, the diagnosis and prognosis of coronary artery disease, and other cardiovascular and renal indications. Founded in 1994, Aderis Pharmaceuticals is headquartered in Hopkinton, Massachusetts and has research facilities in Richmond, Virginia.

Neupro is a trademark of Schwarz Pharma AG.

Certain statements in this news release that are not historical fact constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results of Aderis Pharmaceuticals to be materially different from historical results or from any results expressed or implied by such forward-looking statements. Such statements include, but are not limited to, any statements relating to the Company's development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties, including but not limited to, those risks and uncertainties relating to difficulties or delays in development, testing, regulatory approval, production and marketing of the Company's drug candidates; unexpected adverse side effects or inadequate therapeutic efficacy of the Company's drug candidates that could slow or prevent product development or commercialization; the uncertainty of patent protection for the Company's intellectual property or trade secrets; and the Company's ability to obtain additional financing if necessary. Such statements are based on management's current expectations, but actual results may differ materially due to various factors, some but not all of which may have been mentioned above.

Contact: Sharon Correia Aderis Pharmaceuticals 508-497-2300 ext 224 scorreia@aderis.com Cynthia Isaac The Ruth Group 646-536-7028 cisaac@theruthgroup.com

Aderis Pharmaceuticals

CONTACT: Sharon Correia, Aderis Pharmaceuticals, +1-508-497-2300 ext.224, scorreia@aderis.com; or Cynthia Isaac, The Ruth Group, +1-646-536-7028,cisaac@theruthgroup.com, for Aderis Pharmaceuticals


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->